Literature DB >> 23881961

123I-iomazenil single photon emission computed tomography visualizes recovery of neuronal integrity by bone marrow stromal cell therapy in rat infarct brain.

Hisayasu Saito1, Keiichi Magota, Songji Zhao, Naoki Kubo, Yuji Kuge, Hideo Shichinohe, Kiyohiro Houkin, Nagara Tamaki, Satoshi Kuroda.   

Abstract

BACKGROUND AND
PURPOSE: This study was aimed to assess whether (123)I-iomazenil (IMZ) single photon emission computed tomography can serially monitor the effects of bone marrow stromal cell (BMSC) transplantation on neuronal integrity in infarct brain of rats.
METHODS: The BMSCs were harvested from green fluorescent protein-transgenic rats and were cultured. The rats were subjected to permanent middle cerebral artery occlusion. Their motor function was serially quantified throughout the experiments. The BMSCs or vehicle was stereotactically transplanted into the ipsilateral striatum at 7 days after the insult. Using small-animal single photon emission computed tomography/computed tomography apparatus, the (123)I-IMZ uptake was serially measured at 6 and 35 days after the insult. Finally, fluorescence immunohistochemistry was performed to evaluate the distribution of engrafted cells and their phenotypes.
RESULTS: The distribution of (123)I-IMZ was markedly decreased in the ipsilateral neocortex at 6 days postischemia. The vehicle-transplanted animals did not show a significant change at 35 days postischemia. However, BMSC transplantation significantly improved the distribution of (123)I-IMZ in the peri-infarct neocortex as well as motor function. The engrafted BMSCs were densely distributed around cerebral infarct, and some of them expressed neuronal nuclear antigen and γ-aminobutyric acid type-A receptor.
CONCLUSIONS: The present findings strongly suggest that the BMSCs may enhance functional recovery by improving the neuronal integrity in the peri-infarct area, when directly transplanted into the infarct brain at clinically relevant timing. (123)I-IMZ single photon emission computed tomography may be a promising modality to scientifically prove the beneficial effects of BMSC transplantation on the host brain in clinical situation.

Entities:  

Keywords:  cerebral infarction; iomazenil; mesenchymal stromal cells; tissue therapy; tomography, emission-computed, single-photon

Mesh:

Substances:

Year:  2013        PMID: 23881961     DOI: 10.1161/STROKEAHA.113.001612

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  10 in total

1.  Buyang Huanwu Decoction (BYHWD) Enhances Angiogenic Effect of Mesenchymal Stem Cell by Upregulating VEGF Expression After Focal Cerebral Ischemia.

Authors:  Junhong Yang; Feng Gao; Yunke Zhang; Ying Liu; Di Zhang
Journal:  J Mol Neurosci       Date:  2015-03-22       Impact factor: 3.444

2.  Autologous Bone Marrow Mononuclear Cells Exert Broad Effects on Short- and Long-Term Biological and Functional Outcomes in Rodents with Intracerebral Hemorrhage.

Authors:  Satoshi Suda; Bing Yang; Krystal Schaar; Xiaopei Xi; Jennifer Pido; Kaushik Parsha; Jaroslaw Aronowski; Sean I Savitz
Journal:  Stem Cells Dev       Date:  2015-11-05       Impact factor: 3.272

Review 3.  Fate of graft cells: what should be clarified for development of mesenchymal stem cell therapy for ischemic stroke?

Authors:  Yuka Ikegame; Kentaro Yamashita; Shigeru Nakashima; Yuichi Nomura; Shingo Yonezawa; Yoshitaka Asano; Jun Shinoda; Hideaki Hara; Toru Iwama
Journal:  Front Cell Neurosci       Date:  2014-10-21       Impact factor: 5.505

Review 4.  Current Opinion of Bone Marrow Stromal Cell Transplantation for Ischemic Stroke.

Authors:  Satoshi Kuroda
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-03-15       Impact factor: 1.742

5.  Research on advanced intervention using novel bone marrOW stem cell (RAINBOW): a study protocol for a phase I, open-label, uncontrolled, dose-response trial of autologous bone marrow stromal cell transplantation in patients with acute ischemic stroke.

Authors:  Hideo Shichinohe; Masahito Kawabori; Hiroaki Iijima; Tuyoshi Teramoto; Takeo Abumiya; Naoki Nakayama; Ken Kazumata; Shunsuke Terasaka; Teruyo Arato; Kiyohiro Houkin
Journal:  BMC Neurol       Date:  2017-09-08       Impact factor: 2.474

6.  Mash1-dependent Notch Signaling Pathway Regulates GABAergic Neuron-Like Differentiation from Bone Marrow-Derived Mesenchymal Stem Cells.

Authors:  Qianfa Long; Qiang Luo; Kai Wang; Adrian Bates; Ashok K Shetty
Journal:  Aging Dis       Date:  2017-05-02       Impact factor: 6.745

Review 7.  Cell Therapy for Stroke: Review of Previous Clinical Trials and Introduction of Our New Trials.

Authors:  Hideo Shichinohe; Kiyohiro Houkin
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-06-10       Impact factor: 1.742

8.  Evaluation of Brain Nuclear Medicine Imaging Tracers in a Murine Model of Sepsis-Associated Encephalopathy.

Authors:  Dávid Szöllősi; Nikolett Hegedűs; Dániel S Veres; Ildikó Futó; Ildikó Horváth; Noémi Kovács; Bernadett Martinecz; Ádám Dénes; Daniel Seifert; Ralf Bergmann; Ondřej Lebeda; Zoltán Varga; Zoltán Kaleta; Krisztián Szigeti; Domokos Máthé
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

9.  Intracerebral Transplantation of Mesenchymal Stromal Cell Compounded with Recombinant Peptide Scaffold against Chronic Intracerebral Hemorrhage Model.

Authors:  Soichiro Takamiya; Masahito Kawabori; Tsukasa Kitahashi; Kentaro Nakamura; Yuki Mizuno; Hironobu Yasui; Yuji Kuge; Aki Tanimori; Yasuyuki Takamatsu; Kohei Yuyama; Hideo Shichinohe; Miki Fujimura
Journal:  Stem Cells Int       Date:  2022-07-31       Impact factor: 5.131

10.  [18F]DPA-714 PET imaging shows immunomodulatory effect of intravenous administration of bone marrow stromal cells after transient focal ischemia.

Authors:  Chengbo Tan; Songji Zhao; Kei Higashikawa; Zifeng Wang; Masahito Kawabori; Takeo Abumiya; Naoki Nakayama; Ken Kazumata; Naoyuki Ukon; Hironobu Yasui; Nagara Tamaki; Yuji Kuge; Hideo Shichinohe; Kiyohiro Houkin
Journal:  EJNMMI Res       Date:  2018-05-02       Impact factor: 3.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.